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LETTERS TO THE EDITOR
clinically irrelevant for predicting renal function in pa-Kidney biopsy and
tients with ANCA-associated vasculitis. Our conclusion,
which is quite the opposite, is based on the associationpatient outcome
between the percentage of normal glomeruli (in 3
To the Editor: Bajema et al recently recommended the groups) and serum creatinine levels at three time points.
percentage of normal glomeruli to predict future renal This association was highly significant at all three time
function in patients with vasculitis [1]. The correlation points (Fig. 2). Because of the logarithmic distribution
(not reported) between the percentage of normal glomer- of serum creatinine levels, the Kruskal-Wallis test was
uli and creatinine one year later had a P value ,0.001. used.
Assuming P . 0.0005, as there were 157 biopsies, an upper It is true that serum creatinine levels between the
bound of Z is 3.5, yielding r of 0.28 and r2 0.08, that is, groups overlap to some extent, but it can also be easily
explaining less than 10% of the variation in outcome. This judged from the figures that a lower percentage of nor-
may also be judged by the overlap in creatinine after one mal glomeruli is associated with a higher risk of clinically
year in Figure 2b of the paper. So, at face value, the abnormal serum creatinine levels. Therefore, the per-
conclusion should be that the utility of renal biopsy in centage of normal glomeruli may serve as an indication
predicting outcome is very small and clinically irrelevant, for renal function.
although statistically relevant. Perhaps, however, this con- The number of glomeruli in the biopsies encompasses
clusion could have been otherwise if a number of caveats a broad range, but this is merely a reflection of everyday
had been observed. practice in which we cannot help but deal with renal
The number of glomeruli assessed was 4 to 132 with a biopsies that vary in size. To avoid percentages based
median of 11. The analysis chosen assigns a biopsy with on very few glomeruli, we excluded biopsies which had
4 glomeruli and 100% abnormal glomeruli the same less than four glomeruli from our analysis.
weight as a biopsy with 132 100% abnormal glomeruli. The critique on using the Bonferroni adjustment is
The univariate method of analysis chosen, apart from unfounded. In the referred article by Perneger, it is in
effectively destroying data using Bonferroni [2], prevents fact specifically stated that this adjustment is appropriate
us from understanding relationships between the measure- and prevents one from making excessive claims if the
ments available to the authors. For instance, age or baseline same test is repeated for many parameters, which is the
creatinine might well modify the ability of the percentage case in our analysis.
of normal glomeruli to predict the future course. Clinically, a steady-state level of serum creatinine un-
Finally, the authors had the time course data available der immunosuppressive therapy may be expected at six
for creatinine and might well have used it to analyze months after the acute phase of the disease. Ameliora-
whether the utility of kidney biopsy in predicting the tion of renal function after one year is not to be expected.
future was fully developed after one year. To adjust for disease recurrence within the one-year time
point, we took into account the lowest serum creatinineCorrespondence to Troels Ring, M.D., Department of Nephrology,
Hobrovej 18-22, DK9100, Aalborg, Denmark. level measured during follow-up. For the percentage of
Troels Ring normal glomeruli, however, the results of these clinicalAalborg, Denmark
endpoints were comparable.
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To the Editor: A recent article by Miller, Thai and
Scholey raises the issue of the phenotypic consequencesReply from the authors
of the AT1-R gene polymorphism [1]. These authors dem-In the foregoing letter it is stated—at face value from
onstrate a clear relationship between the A/C polymor-our data—that the percentage of normal glomeruli is
phism at position 1166 of the gene and the renal hemody-
namics under basal conditions and in response to Ang II
or to an AT1 receptor antagonist. They concluded fromÓ 2000 by the International Society of Nephrology
2173
2174
their data that there is an increased Ang II “activity” in diastolic pressure, which was higher in the subjects bearing
this allele in accordance with previously published resultsthe subjects bearing the C allele (AC and CC) compared
[4]. It is thus noteworthy that, in contrast with other pa-with the homozygous subjects for the A allele (AA). No
rameters of the renin-angiotensin-aldosterone systemattempt was made in this article to search for a biological
(converting enzyme, angiotensinogen and aldosteroneintermediate phenotype, directly related to the gene stud-
synthase) for which associations between gene polymor-ied, which in this case would be the AT1-R itself. In fact,
phisms and the corresponding plasma concentrations arethe differences observed between the AA subjects and
found [3], no such direct effect of the AT1-R A 1166 Cthose with the C allele may result from many possible
polymorphism on the gene product has been demon-mechanisms, as discussed by the authors and also by
strated until now.Blantz in the editorial published in the same issue of the
Raymond Ardaillou and F. Soubrierjournal [2]. The only method to relate these differences Paris, France
to a change in the expression of AT1-R would have been
to evaluate the equilibrium-binding parameters of this
Correspondence to R. Ardaillou, INSERM U. 489, Hoˆpital Tenon,receptor (Bmax and KD) on accessible cells such as platelets 4 rue de la Chine, 75970 Paris cedex 20, France.
collected from the subjects studied. We performed such
a study in a recently published paper [3], but were unable REFERENCES
to detect any correlation between the KD or the Bmax of 1. Miller JA, Thai K, Scholey JW: Angiotensin II type I receptor
the Ang II binding sites on platelets and the A 1166 C gene polymorphism predicts the response to losartan and angiotensin
II. Kidney Int 56:2173–2180, 1999polymorphism in a normal population. We hypothesized
2. Blantz RC: Why are some people more receptive to angiotensinthat because of their low expression, the AT1-R in platelets II? Kidney Int 56:2316–2317, 1999
either are not or are weakly submitted to transcriptional 3. Paillard F, Chansel D, Brand E, Benetos A, Thomas F, Czekal-
ski S, Ardaillou R, Soubrier F: Genotype-phenotype relationshipsregulatory mechanisms that act in the other target tissues
for the renin-angiotensin-aldosterone system in a normal population.
of Ang II. Therefore, our results indicate that this mea- Hypertension 34:423–429, 1999
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